Parameters | Good prognosis group (N = 235) | Poor prognosis group (N = 55) | P |
---|---|---|---|
Age (year) | 66.46 ± 5.21 | 67.53 ± 4.61 | 0.1637 |
Hypertension | |||
No | 165 (70.21%) | 39 (70.91%) | 0.6694 |
Yes | 70 (29.79%) | 16 (29.09%) | |
Diabetes | |||
No | 190 (80.85%) | 45 (81.82%) | 0.8692 |
Yes | 45 (19.15%) | 10 (18.18%) | |
PSA (ng/mL) | |||
< 20 | 140 (59.57%) | 20 (36.36%) | 0.0018 |
≥ 20 | 95 (40.43%) | 35 (63.64%) | |
Gleason score | |||
< 8 | 135 (57.45%) | 22 (40.00%) | 0.0194 |
≥ 8 | 100 (42.55%) | 33 (60.00%) | |
T stage | |||
T2 | 109 (46.38%) | 16 (29.09%) | 0.0197 |
T3-4 | 126 (53.62%) | 39 (70.91%) | |
Lymph node metastasis | |||
No | 144 (61.28%) | 25 (45.45%) | 0.0322 |
Yes | 91 (38.72%) | 30 (54.55%) | |
Seminal vesicle invasion | |||
No | 137 (58.30%) | 24 (43.64%) | 0.0489 |
Yes | 98 (41.70%) | 31 (56.36%) | |
Neutrophils (×109/L) | 3.31 (1.24,5.21) | 3.62 (2.28,5.48) | 0.0166 |
Lymphocytes (×109/L) | 1.84 (0.80,3.25) | 1.45 (0.82,2.41) | < 0.0001 |
Platelets (×109/L) | 229 (163,355) | 284 (207,332) | < 0.0001 |
Preoperative SII | 423.70 (117.10,1197) | 692.10 (275.7,1275) | < 0.0001 |
Ki-67 index | 13.84 ± 2.47 | 18.14 ± 3.38 | < 0.0001 |